CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasted to Earn Q3 2021 Earnings of ($1.37) Per Share


Share on StockTwits

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Truist Securiti decreased their Q3 2021 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 11th. Truist Securiti analyst J. Lee now anticipates that the company will post earnings per share of ($1.37) for the quarter, down from their prior estimate of ($1.36). Truist Securiti also issued estimates for CRISPR Therapeutics’ Q4 2021 earnings at ($1.46) EPS, FY2021 earnings at ($5.53) EPS and FY2022 earnings at ($6.28) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 2nd. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.14). The business had revenue of $0.15 million during the quarter, compared to the consensus estimate of $2.22 million. CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%. During the same period in the previous year, the company posted $2.40 EPS. The company’s revenue for the quarter was down 99.9% compared to the same quarter last year.

Other equities research analysts have also issued reports about the company. Canaccord Genuity increased their price target on CRISPR Therapeutics from $120.00 to $151.00 and gave the stock a “buy” rating in a research report on Monday, December 7th. Truist raised their price target on CRISPR Therapeutics from $170.00 to $210.00 in a research report on Tuesday. Chardan Capital increased their price target on CRISPR Therapeutics from $110.00 to $166.00 and gave the stock a “buy” rating in a report on Thursday, December 10th. BidaskClub lowered shares of CRISPR Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 30th. Finally, Royal Bank of Canada started coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 22nd. They issued a “sector perform” rating and a $110.00 price objective for the company. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have assigned a buy rating to the company. CRISPR Therapeutics currently has a consensus rating of “Buy” and an average price target of $136.07.

Shares of CRSP opened at $193.84 on Thursday. CRISPR Therapeutics has a 1 year low of $32.30 and a 1 year high of $210.39. The stock has a 50 day simple moving average of $155.02 and a 200-day simple moving average of $107.29. The stock has a market cap of $13.80 billion, a PE ratio of -59.46 and a beta of 2.37.

Several institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC raised its holdings in CRISPR Therapeutics by 30.4% during the 3rd quarter. ARK Investment Management LLC now owns 8,457,320 shares of the company’s stock worth $707,370,000 after purchasing an additional 1,974,069 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $112,187,000. FMR LLC raised its stake in shares of CRISPR Therapeutics by 18.8% in the second quarter. FMR LLC now owns 1,041,810 shares of the company’s stock worth $76,563,000 after purchasing an additional 164,796 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in CRISPR Therapeutics by 64.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 406,815 shares of the company’s stock valued at $34,576,000 after acquiring an additional 159,481 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 79.6% during the second quarter. Vanguard Group Inc. now owns 333,554 shares of the company’s stock worth $24,513,000 after purchasing an additional 147,782 shares during the last quarter. 66.43% of the stock is currently owned by institutional investors.

In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 171,004 shares of the business’s stock in a transaction that occurred on Monday, December 7th. The shares were sold at an average price of $154.53, for a total transaction of $26,425,248.12. Following the completion of the transaction, the director now directly owns 40,648 shares in the company, valued at $6,281,335.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Tony W. Ho sold 23,551 shares of the company’s stock in a transaction on Monday, December 21st. The stock was sold at an average price of $149.23, for a total value of $3,514,515.73. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 355,203 shares of company stock worth $51,155,283. Corporate insiders own 17.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Read More: Understanding dividend yield and dividend payout ratio

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.